NASDAQ:AGRX Agile Therapeutics - AGRX Stock Forecast, Price & News Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding Agile Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. $0.27 0.00 (0.00%) (As of 01/30/2023 12:00 AM ET) Add Compare Share Share Today's Range$0.27▼$0.2950-Day Range$0.18▼$0.3152-Week Range$0.18▼$15.60Volume860,458 shsAverage Volume1.02 million shsMarket Capitalization$10.94 millionP/E RatioN/ADividend YieldN/APrice TargetN/A ProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsShort InterestSocial MediaSustainability Agile Therapeutics MarketRank™ ForecastAnalyst RatingN/AUpside/DownsideN/AShort InterestHealthy1.72% of Float Sold ShortDividend StrengthN/ASustainability-1.59Upright™ Environmental ScoreNews Sentiment1.44Based on 3 Articles This WeekInsider TradingN/AProj. Earnings GrowthGrowingFrom ($2.12) to ($0.25) Per ShareSee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.2.10 out of 5 starsMedical Sector562nd out of 1,055 stocksPharmaceutical Preparations Industry280th out of 518 stocks N/A Analyst's Opinion Consensus RatingThere is not enough analysis data for Agile Therapeutics. Previous Next 4.0 Short Interest Percentage of Shares Shorted1.72% of the float of Agile Therapeutics has been sold short.Short Interest Ratio / Days to CoverAgile Therapeutics has a short interest ratio ("days to cover") of 0.8, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Agile Therapeutics has recently decreased by 0.09%, indicating that investor sentiment is improving. Previous Next 0.0 Dividend Strength Dividend YieldAgile Therapeutics does not currently pay a dividend.Dividend GrowthAgile Therapeutics does not have a long track record of dividend growth. Previous Next 4.0 Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreAgile Therapeutics has received a 56.48% net impact score from Upright. The largest positive contribution comes from its "Physical diseases" impact, which is false driven by its "Estradiol medication" and "Clinical research services for physical health" products. See details.Environmental SustainabilityThe Environmental Impact score for Agile Therapeutics is -1.59. Previous Next 4.1 News and Social Media Coverage News SentimentAgile Therapeutics has a news sentiment score of 1.44. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.72 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 3 news articles for Agile Therapeutics this week, compared to 1 article on an average week.Search Interest31 people have searched for AGRX on MarketBeat in the last 30 days. This is an increase of 121% compared to the previous 30 days.MarketBeat Follows5 people have added Agile Therapeutics to their MarketBeat watchlist in the last 30 days. This is an increase of 25% compared to the previous 30 days. Previous Next 0.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Agile Therapeutics insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 4.70% of the stock of Agile Therapeutics is held by insiders.Percentage Held by InstitutionsOnly 5.70% of the stock of Agile Therapeutics is held by institutions. Previous Next 1.3 Earnings and Valuation Earnings GrowthEarnings for Agile Therapeutics are expected to grow in the coming year, from ($2.12) to ($0.25) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Agile Therapeutics is -0.02, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Agile Therapeutics is -0.02, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioAgile Therapeutics has a P/B Ratio of 0.09. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here About Agile Therapeutics (NASDAQ:AGRX) StockAgile Therapeutics, Inc. is a healthcare company, which engages in the development and commercialization of transdermal patch. Its lead product candidate, Twirla, also known as AG200-15, is an investigational low-dose, non-daily prescription contraceptive. The company was founded by Chien Te Yen on December 22, 1997 and is headquartered in Princeton, NJ.Read More Receive AGRX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Agile Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address AGRX Stock News HeadlinesJanuary 31, 2023 | americanbankingnews.comAgile Therapeutics (NASDAQ:AGRX) Coverage Initiated by Analysts at StockNews.comJanuary 26, 2023 | finance.yahoo.comAgile Therapeutics Announces Distribution of Series C Preferred Stock to its Holders of Common StockJanuary 31, 2023 | Porter & Company (Ad)Is This The End of Capitalism?EXPOSED: The establishment plot to disenfranchise and impoverish millions of Americans…January 19, 2023 | benzinga.comAgile Therapeutics: This BioPharma Firm Is Nimbly Solving Unmet Needs For WomenJanuary 18, 2023 | finance.yahoo.comIs Ardelyx (ARDX) Outperforming Other Medical Stocks This Year?January 10, 2023 | markets.businessinsider.comMaxim Group Keeps Their Buy Rating on Agile Therapeutics (AGRX)January 9, 2023 | msn.comAgile stock rises as 2023 revenue seen up to $30MJanuary 9, 2023 | finance.yahoo.comAgile Therapeutics Provides Updates on 2022 Twirla Performance and 2023 Commercial PlanJanuary 31, 2023 | Porter & Company (Ad)The Next Big Crisis Is HereYou just can’t see it yet because it’s NOT a banking, financial, or economic crisis… it’s far worse and threatens every dollar in your retirement account.December 30, 2022 | msn.comHC Wainwright & Co. Maintains Buy Rating for Agile Therapeutics: Here's What You Need To KnowDecember 23, 2022 | seekingalpha.comAGRX Agile Therapeutics, Inc.December 21, 2022 | markets.businessinsider.comEQS-News: This Biotech Company is Pursuing Positive Cash Flow In 2023December 20, 2022 | benzinga.comThis Biotech Company is Pursuing Positive Cash Flow In 2023December 1, 2022 | finance.yahoo.comAgile Therapeutics To Present At The Upcoming RHK Capital Disruptive Growth ConferenceNovember 29, 2022 | benzinga.comAgile Therapeutics Earnings Perspective: Return On Capital EmployedNovember 15, 2022 | finance.yahoo.comWomen’s Healthcare Company Agile Therapeutics Says It Believes It Has An Effective Business Plan In Place For Growth And Generating Positive Cash FlowNovember 8, 2022 | seekingalpha.comAgile Therapeutics, Inc. (AGRX) Q3 2022 Earnings Call TranscriptNovember 8, 2022 | finance.yahoo.comAgile Therapeutics Reports Third Quarter 2022 Financial Results and Provides Corporate UpdateOctober 26, 2022 | finance.yahoo.comAgile Therapeutics to Report Third Quarter 2022 Financial Results and Provide Business Update on Monday, November 7, 2022October 26, 2022 | finance.yahoo.comCan This Company’s Birth Control Patch Disrupt The Contraceptive Market?October 21, 2022 | finance.yahoo.comNASDAQ: AGRX Agile Therapeutics Anticipates Increased Growth In Q3 of 2022October 7, 2022 | finance.yahoo.comAgile Therapeutics Announces Reorganization of Leadership TeamOctober 5, 2022 | theglobeandmail.comAgile Therapeutics: Top 10 Undervalued Healthcare Stocks on NAS (AGRX)September 6, 2022 | finance.yahoo.comAgile Therapeutics to Present at the H.C. Wainwright 24th Annual Global Investment ConferenceAugust 12, 2022 | proactiveinvestors.comAgile Therapeutics gains traction with female contraception brand as it targets unmet medical needsAugust 12, 2022 | finance.yahoo.comAgile Therapeutics (AGRX) Q2 2022 Earnings Call TranscriptAugust 11, 2022 | seekingalpha.comAgile Therapeutics, Inc. (AGRX) CEO Al Altomari on Q2 2022 Results - Earnings Call TranscriptSee More Headlines View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart Receive AGRX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Agile Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address AGRX Company Calendar Last Earnings11/07/2022Today1/31/2023Next Earnings (Estimated)3/29/2023Fiscal Year End12/31/2023Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:AGRX CUSIPN/A CIK1261249 Webwww.agiletherapeutics.com Phone(609) 683-1880FaxN/AEmployees28Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)($15.02) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-74,890,000.00 Net Margins-797.48% Pretax Margin-853.10% Return on Equity-1,074.50% Return on Assets-186.41% Debt Debt-to-Equity RatioN/A Current Ratio1.33 Quick Ratio1.17 Sales & Book Value Annual Sales$8.40 million Price / Sales1.30 Cash FlowN/A Price / Cash FlowN/A Book Value$3.05 per share Price / Book0.09Miscellaneous Outstanding Shares40,615,000Free Float38,706,000Market Cap$10.94 million OptionableOptionable Beta1.08 Key ExecutivesAl AltomariChairman & Chief Executive OfficerJason ButchChief Accounting & Financial Officer, VPPaul KornerChief Medical OfficerRobert G. ConwayChief Supply Chain Officer & Senior Vice PresidentGeoffrey P. GilmoreChief Administrative OfficerKey CompetitorsAptevo TherapeuticsNASDAQ:APVOCan-Fite BioPharmaNYSE:CANFLiminal BioSciencesNASDAQ:LMNLDiffusion PharmaceuticalsNASDAQ:DFFNLixte BiotechnologyNASDAQ:LIXTView All CompetitorsInsiders & InstitutionsBlackRock Inc.Bought 256,227 shares on 11/15/2022Ownership: 0.748%Alfred AltomariBought 50,000 shares on 8/26/2022Total: $22,500.00 ($0.45/share)View All Insider TransactionsView All Institutional Transactions AGRX Stock - Frequently Asked Questions Should I buy or sell Agile Therapeutics stock right now? 1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Agile Therapeutics in the last year. There are currently 1 buy rating for the stock. The consensus among Wall Street analysts is that investors should "buy" AGRX shares. View AGRX analyst ratings or view top-rated stocks. How have AGRX shares performed in 2023? Agile Therapeutics' stock was trading at $0.2270 at the beginning of 2023. Since then, AGRX stock has increased by 18.7% and is now trading at $0.2694. View the best growth stocks for 2023 here. When is Agile Therapeutics' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Wednesday, March 29th 2023. View our AGRX earnings forecast. How were Agile Therapeutics' earnings last quarter? Agile Therapeutics, Inc. (NASDAQ:AGRX) posted its earnings results on Monday, November, 7th. The specialty pharmaceutical company reported ($0.23) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.30) by $0.07. The specialty pharmaceutical company earned $3 million during the quarter, compared to analysts' expectations of $2.46 million. Agile Therapeutics had a negative trailing twelve-month return on equity of 1,074.50% and a negative net margin of 797.48%. When did Agile Therapeutics' stock split? Shares of Agile Therapeutics reverse split on Wednesday, April 27th 2022. The 1-40 reverse split was announced on Wednesday, April 27th 2022. The number of shares owned by shareholders was adjusted after the closing bell on Wednesday, April 27th 2022. An investor that had 100 shares of stock prior to the reverse split would have 3 shares after the split. What guidance has Agile Therapeutics issued on next quarter's earnings? Agile Therapeutics updated its FY 2023 earnings guidance on Monday, January, 9th. The company provided earnings per share (EPS) guidance of for the period. The company issued revenue guidance of $25.00 million-$30.00 million, compared to the consensus revenue estimate of $20.26 million. What other stocks do shareholders of Agile Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some companies that other Agile Therapeutics investors own include OPKO Health (OPK), Sorrento Therapeutics (SRNE), VBI Vaccines (VBIV), Amarin (AMRN), Inovio Pharmaceuticals (INO), SCYNEXIS (SCYX), Nabriva Therapeutics (NBRV), AcelRx Pharmaceuticals (ACRX), Micron Technology (MU) and Novavax (NVAX). What is Agile Therapeutics' stock symbol? Agile Therapeutics trades on the NASDAQ under the ticker symbol "AGRX." Who are Agile Therapeutics' major shareholders? Agile Therapeutics' stock is owned by a number of institutional and retail investors. Top institutional shareholders include Concourse Financial Group Securities Inc. (0.00%). Insiders that own company stock include Alfred Altomari, Dennis Reilly, Jason Butch, Life Sciences Maste Perceptive and Perceptive Advisors Llc. View institutional ownership trends. How do I buy shares of Agile Therapeutics? Shares of AGRX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. What is Agile Therapeutics' stock price today? One share of AGRX stock can currently be purchased for approximately $0.27. How much money does Agile Therapeutics make? Agile Therapeutics (NASDAQ:AGRX) has a market capitalization of $10.94 million and generates $8.40 million in revenue each year. The specialty pharmaceutical company earns $-74,890,000.00 in net income (profit) each year or ($15.02) on an earnings per share basis. How can I contact Agile Therapeutics? Agile Therapeutics' mailing address is 101 POOR FARM ROAD, PRINCETON NJ, 08540. The official website for the company is www.agiletherapeutics.com. The specialty pharmaceutical company can be reached via phone at (609) 683-1880 or via email at info@agiletherapeutics.com. This page (NASDAQ:AGRX) was last updated on 1/31/2023 by MarketBeat.com Staff Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.